EUVIMEDEUVIMED entdecken
Crossref

Intralesional methotrexate for crateriform and noncrateriform keratinocytic tumours: a retrospective case series of 33 patients

Pablo López Sanz iD, Eduardo Escario Travesedo, Joan Àngel Baldó iD, Cristina Grau Salvat, Inmaculada Gil Faure, Antoni Azón Masoliver

Clinical and Experimental Dermatology · 24.07.2026 · 51 (8) · 1470-1473

DOI: 10.1093/ced/llag119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 16.03.2026. Verfasst von Pablo López Sanz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitari Sant Joan de Reus, Catalunya, Spain. Hauptthemen laut MEDLINE: Methotrexate, Skin Neoplasms, Keratoacanthoma, Antimetabolites, Antineoplastic. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Differentiating keratoacanthoma from cutaneous squamous cell carcinoma (cSCC) remains challenging, particularly in crateriform keratinocytic tumours with clinicopathological overlap and diagnostic variability. Although histopathology is essential for diagnosis, its ability to reliably predict biological behaviour and therapeutic response in this setting is limited. We conducted a retrospective single-centre study of 33 patients, mean (SD) age 78 (13.1) years, with keratinocytic tumours treated with intralesional methotrexate between 2018 and 2023, to assess whether clinical morphology predicted treatment outcome more reliably than histological classification. Complete resolution was achieved in 20/33 (61%) patients after a mean of 4.5 injections. Crateriform symmetrical tumours showed significantly higher response rates than noncrateriform tumours (85% vs. 23%; P < 0.001). Tumour size and histological subtype were not significantly associated with outcome. Adverse events were mild and reversible. Clinical crateriform morphology may represent a practical predictor of response to intralesional methotrexate and may help to guide therapeutic decision making in patients with equivocal histopathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateSkin NeoplasmsKeratoacanthomaAntimetabolites, AntineoplasticHumansRetrospective StudiesFemaleMaleInjections, IntralesionalAgedTreatment OutcomeAged, 80 and overCutaneous Squamous Cell CarcinomaDiagnosis, DifferentialMiddle Aged

Substanzen

MethotrexateAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitari Sant Joan de Reus, Catalunya, Spain.
  • Department of Dermatology, Hospital General Universitario de Albacete, Castilla-La Mancha, Spain.

ORCID-Profile: Pablo López Sanz, Joan Àngel Baldó

Zitieren

APA

López Sanz, P., Escario Travesedo, E., Àngel Baldó, J., Grau Salvat, C., Gil Faure, I., & Azón Masoliver, A. (2026). Intralesional methotrexate for crateriform and noncrateriform keratinocytic tumours: a retrospective case series of 33 patients. Clinical and Experimental Dermatology, 51(8), 1470-1473. https://doi.org/10.1093/ced/llag119

Vancouver

López Sanz P, Escario Travesedo E, Àngel Baldó J, Grau Salvat C, Gil Faure I, Azón Masoliver A. Intralesional methotrexate for crateriform and noncrateriform keratinocytic tumours: a retrospective case series of 33 patients. Clinical and Experimental Dermatology. 2026;51(8):1470-1473. doi:10.1093/ced/llag119

BibTeX
@article{LpezSanz2026,
  author = {López Sanz, Pablo and Escario Travesedo, Eduardo and Àngel Baldó, Joan and Grau Salvat, Cristina and Gil Faure, Inmaculada and Azón Masoliver, Antoni},
  title = {Intralesional methotrexate for crateriform and noncrateriform keratinocytic tumours: a retrospective case series of 33 patients},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  volume = {51},
  number = {8},
  pages = {1470--1473},
  doi = {10.1093/ced/llag119}
}
Kostenlos starten →